Literature DB >> 2727550

Plasminogen activation in plasma of patients with systemic lupus erythematosus.

N Negoro1, Y Kanayama, T Takeda, M Fujisawa, M Okamura, T Inoue.   

Abstract

We measured alpha 2-plasmin inhibitor-plasmin complexes (PI-PC) in plasma of patients with systemic lupus erythematosus (SLE) to examine the plasminogen activation in SLE. The plasma PI-PC level in 23 patients with SLE was significantly higher than that in 18 normal subjects (P less than 0.001) and the SLE patients with nephrotic syndrome had higher plasma PI-PC levels than those without nephrotic syndrome (P less than 0.01). In addition, the plasma PI-PC level was significantly correlated with the level of plasma C3 breakdown products (iC3b/C3dg) in the patients with SLE (r = 0.53, P less than 0.01). These results suggest that plasminogen is activated in plasma of patients with SLE and that the plasminogen activation may be associated with the activation of complement in SLE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2727550     DOI: 10.1007/bf00270984

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

1.  Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage.

Authors:  T Sacks; C F Moldow; P R Craddock; T K Bowers; H S Jacob
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

2.  Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus.

Authors:  M Cronlund; J Hardin; J Burton; L Lee; E Haber; K J Bloch
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

3.  Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q.

Authors:  F C Hay; L J Nineham; I M Roitt
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

4.  Direct quantitation of activated C3 in human plasma with monoclonal anti-iC3b-C3d-neoantigen.

Authors:  Y Kanayama; Y Kurata; R McMillan; J D Tamerius; N Negoro; J G Curd
Journal:  J Immunol Methods       Date:  1986-04-03       Impact factor: 2.303

5.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

6.  Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury.

Authors:  P A Ward; G O Till; R Kunkel; C Beauchamp
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

7.  Serum factors from patients with systemic lupus erythematosus enhancing superoxide generation by normal neutrophils.

Authors:  M Shingu; M Oribe; T Todoroki; K Tatsukawa; K Tomo-oka; M Yasuda; M Nobunaga
Journal:  J Invest Dermatol       Date:  1983-09       Impact factor: 8.551

8.  Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).

Authors:  W Lloyd; P H Schur
Journal:  Medicine (Baltimore)       Date:  1981-05       Impact factor: 1.889

9.  Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis.

Authors:  H L Nossel
Journal:  Nature       Date:  1981-05-14       Impact factor: 49.962

10.  The conversion of C'IS to C'1 esterase by plasmin and trypsin.

Authors:  O D Ratnoff; G B Naff
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.